Advertisement

Resistant Hypertension: Diagnosis and Management

      Resistant hypertension is defined as high blood pressure requiring 3 or more medications for adequate control or controlled blood pressure requiring 4 or more medications. Considering the growing prevalence of hypertension and the strong link with cardiovascular disease, it is vital to understand the causes and treatment of resistant hypertension. This review article starts with an overview of the prevalence and little-known pathophysiology of resistant hypertension. Afterward, we discuss the evaluation and management of suspected secondary resistant hypertension in 2 broad categories: pseudoresistant hypertension and true resistant hypertension. Strategies for the identification and management of pseudoresistant hypertension are addressed. In addition, causes of true resistant hypertension, such as obstructive sleep apnea, primary aldosteronism, and renal artery stenosis, are examined along with their respective treatments. Finally, treatment of resistant hypertension is reviewed including pharmacologic treatments and novel procedural interventions for resistant hypertension. Overall, the review hopes to provide practitioners with a cohesive approach for the diagnosis and treatment of resistant hypertension.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Saklayen M.G.
        • Deshpande N.V.
        Timeline of history of hypertension treatment.
        Front Cardiovasc Med. 2016; 3: 3
        • Persson G.
        • Ekwall B.
        • Furst C.
        A clinical trial of guanoxan (Envacar) in hypertension resistant to common drugs.
        Acta Med Scand. 1967; 182: 567-574
        • Dargie H.J.
        • Dollery C.T.
        • Daniel J.
        Labetalol in resistant hypertension.
        Br J Clin Pharmacol. 1976; 3: 751-755
        • Pierdomenico S.D.
        • Lapenna D.
        • Bucci A.
        • et al.
        Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.
        Am J Hypertens. 2005; 18: 1422-1428
        • Fagard R.H.
        • Cornelissen V.A.
        Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis.
        J Hypertens. 2007; 25: 2193-2198
        • Fatemi O.
        • Goa C.
        • Faselis C.
        • Kokkinos P.
        • Papademetriou V.
        Improvement in all-cause mortality with blood pressure control in a group of US Veterans with drug-resistant hypertension.
        J Clin Hypertens. 2016; 18: 33-39
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Circulation. 2008; 117: e510-e526
        • Judd E.
        • Calhoun D.A.
        Apparent and true resistant hypertension: definition, prevalence and outcomes.
        J Hum Hypertens. 2014; 28: 463-468
        • Dudenbostel T.
        • Siddiqui M.
        • Oparil S.
        • Calhoun D.A.
        Refractory hypertension: a novel phenotype of antihypertensive treatment failure.
        Hypertension. 2016; 67: 1085-1092
        • Sim J.J.
        • Bhandari S.K.
        • Shi J.
        • et al.
        Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.
        Mayo Clin Proc. 2013; 88: 1099-1107
        • Daugherty S.L.
        • Powers J.D.
        • Magid D.J.
        • et al.
        Incidence and prognosis of resistant hypertension in hypertensive patients.
        Circulation. 2012; 125: 1635-1642
        • Calhoun D.A.
        Fluid retention, aldosterone excess, and treatment of resistant hypertension.
        Lancet Diabetes Endocrinol. 2018; 6: 431-433
        • Taler S.J.
        • Textor S.C.
        • Augustine J.E.
        Resistant hypertension: comparing hemodynamic management to specialist care.
        Hypertension. 2002; 39: 982-988
        • Dudenbostel T.
        • Acelajado M.C.
        • Pisoni R.
        • Li P.
        • Oparil S.
        • Calhoun D.A.
        Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure.
        Hypertension. 2015; 66: 126-133
        • Ostchega Y.
        • Hughes J.P.
        • Nwankwo T.
        • Zhang G.
        Mean mid-arm circumference and blood pressure cuff sizes for US children, adolescents and adults: National Health and Nutrition Examination Survey, 2011-2016.
        Blood Press Monit. 2018; 23: 305-311
        • Ramli A.
        • Halmey N.
        • Teng C.
        White coat effect and white coat hypertension: one and the same?.
        Malays Fam Physician. 2008; 3: 158-161
        • Verdecchia P.
        • Staessen J.A.
        • White W.B.
        • Imai Y.
        • O'Brien E.T.
        Properly defining white coat hypertension.
        Eur Heart J. 2002; 23: 106-109
        • Grigoryan L.
        • Pavlik V.N.
        • Hyman D.J.
        Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence.
        J Am Soc Hypertens. 2013; 7: 471-476
        • Tomaszewski M.
        • White C.
        • Patel P.
        • et al.
        High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.
        Heart. 2014; 100: 855-861
        • Bunker J.
        • Chang C.L.
        • Chapman N.
        • et al.
        True resistant hypertension following observed drug ingestion: a systematic evaluation.
        J Clin Hypertens. 2017; 19: 250-255
        • Nishizaka M.K.
        • Pratt-Ubunama M.
        • Zaman M.A.
        • Cofield S.
        • Calhoun D.A.
        Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.
        Am J Hypertens. 2005; 18: 805-812
        • He F.J.
        • Li J.
        • Macgregor G.A.
        Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials.
        BMJ. 2013; 346: f1325
        • Jurca S.J.
        • Elliott W.J.
        Common substances that may contribute to resistant hypertension, and recommendations for limiting their clinical effects.
        Curr Hypertens Rep. 2016; 18: 73
        • Grossman E.
        • Messerli F.H.
        Drug-induced hypertension: an unappreciated cause of secondary hypertension.
        Am J Med. 2012; 125: 14-22
        • Husain K.
        • Ansari R.A.
        • Ferder L.
        Alcohol-induced hypertension: mechanism and prevention.
        World J Cardiol. 2014; 6: 245-252
        • Ferdinand K.C.
        Substance abuse and hypertension.
        J Clin Hypertens. 2000; 2: 37-40
        • Chiong J.R.
        • Aronow W.S.
        • Khan I.A.
        • et al.
        Secondary hypertension: current diagnosis and treatment.
        Int J Cardiol. 2008; 124: 6-21
        • Thase M.E.
        Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.
        J Clin Psychiatry. 1998; 59: 502-508
        • Hoorn E.J.
        • Walsh S.B.
        • McCormick J.A.
        • Zietse R.
        • Unwin R.J.
        • Ellison D.H.
        Pathogenesis of calcineurin inhibitor-induced hypertension.
        J Nephrol. 2012; 25: 269-275
        • Shimada N.
        • Saka S.
        • Sekizuka K.
        • et al.
        Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients.
        Ren Fail. 2003; 25: 569-578
        • Laragh J.H.
        Oral contraceptives—induced hypertension—nine years later.
        Am J Obstet Gynecol. 1976; 126: 141-147
        • Logan A.G.
        • Perlikowski S.M.
        • Mente A.
        • et al.
        High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.
        J Hypertens. 2001; 19: 2271-2277
        • Peppard P.E.
        • Young T.
        • Palta M.
        • Skatrud J.
        Prospective study of the association between sleep-disordered breathing and hypertension.
        N Engl J Med. 2000; 342: 1378-1384
        • Pedrosa R.P.
        • Drager L.F.
        • Gonzaga C.C.
        • et al.
        Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.
        Hypertension. 2011; 58: 811-817
        • Demede M.
        • Pandey A.
        • Zizi F.
        • et al.
        Resistant hypertension and obstructive sleep apnea in the primary-care setting.
        Int J Hypertens. 2011; 2011 ([published online June 8, 2011]): 340929https://doi.org/10.4061/2011/340929
        • Goodfriend T.L.
        • Calhoun D.A.
        Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.
        Hypertension. 2004; 43: 518-524
        • Ehrhart-Bornstein M.
        • Lamounier-Zepter V.
        • Schraven A.
        • et al.
        Human adipocytes secrete mineralocorticoid-releasing factors.
        Proc Natl Acad Sci U S A. 2003; 100: 14211-14216
        • Wolley M.J.
        • Stowasser M.
        Resistant hypertension and chronic kidney disease: a dangerous liaison.
        Curr Hypertens Rep. 2016; 18: 36
        • Brown M.A.
        • Whitworth J.A.
        Hypertension in human renal disease.
        J Hypertens. 1992; 10: 701-712
        • Kincaid-Smith P.
        • Whitworth J.A.
        Pathogenesis of hypertension in chronic renal disease.
        Semin Nephrol. 1988; 8: 155-162
        • Judd E.
        • Calhoun D.A.
        Management of hypertension in CKD: beyond the guidelines.
        Adv Chronic Kidney Dis. 2015; 22: 116-122
        • Huysmans F.T.
        • Thien T.
        • Koene R.A.
        Renin-angiotensin system and blood volume in patients with dialysis-resistant hypertension.
        Neth J Med. 1980; 23: 74-78
        • Lewis E.J.
        • Hunsicker L.G.
        • Bain R.P.
        • Rohde R.D.
        The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
        N Engl J Med. 1993; 329: 1456-1462
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
        J Renin Angiotensin Aldosterone Syst. 2000; 1: 328-335
        • Douma S.
        • Petidis K.
        • Doumas M.
        • et al.
        Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.
        Lancet. 2008; 371: 1921-1926
        • Thatcher S.E.
        A brief introduction into the renin-angiotensin-aldosterone system: new and old techniques.
        Methods Mol Biol. 2017; 1614: 1-19
        • Rayner B.L.
        • Opie L.H.
        • Davidson J.S.
        The aldosterone/renin ratio as a screening test for primary aldosteronism.
        S Afr Med J. 2000; 90: 394-400
        • Gallay B.J.
        • Ahmad S.
        • Xu L.
        • Toivola B.
        • Davidson R.C.
        Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.
        Am J kidney Dis. 2001; 37: 699-705
        • Stowasser M.
        • Taylor P.J.
        • Pimenta E.
        • Ahmed A.H.
        • Gordon R.D.
        Laboratory investigation of primary aldosteronism.
        Clin Biochem Rev. 2010; 31: 39-56
        • Holland O.B.
        • Brown H.
        • Kuhnert L.
        • Fairchild C.
        • Risk M.
        • Gomez-Sanchez C.E.
        Further evaluation of saline infusion for the diagnosis of primary aldosteronism.
        Hypertension. 1984; 6: 717-723
        • Weinberger M.H.
        • Fineberg N.S.
        The diagnosis of primary aldosteronism and separation of two major subtypes.
        Arch Intern Med. 1993; 153: 2125-2129
        • Ganguly A.
        Primary aldosteronism.
        N Engl J Med. 1998; 339: 1828-1834
        • Pedrinelli R.
        • Graziadei L.
        • Taddei S.
        • et al.
        A renin-secreting tumor.
        Nephron. 1987; 46: 380-385
        • Fallo F.
        • Armanini D.
        • Maragno I.
        • Mantero F.
        Plasma renin activity in coarctation of the aorta before and after surgical correction.
        Br Heart J. 1978; 40: 1415-1418
        • Textor S.C.
        • Lerman L.
        Renovascular hypertension and ischemic nephropathy.
        Am J Hypertens. 2010; 23: 1159-1169
        • Treadway K.K.
        • Slater E.E.
        Renovascular hypertension.
        Annu Rev Med. 1984; 35: 665-692
        • Weber B.R.
        • Dieter R.S.
        Renal artery stenosis: epidemiology and treatment.
        Int J Nephrol Renovasc Dis. 2014; 7: 169-181
      1. Detection, evaluation, and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension.
        Arch Intern Med. 1987; 147: 820-829
        • Safian R.D.
        • Textor S.C.
        Renal-artery stenosis.
        N Engl J Med. 2001; 344: 431-442
        • McNeil B.J.
        • Varady P.D.
        • Burrows B.A.
        • Adelstein S.J.
        Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease.
        N Engl J Med. 1975; 293: 216-221
        • Vasbinder G.B.
        • Nelemans P.J.
        • Kessels A.G.
        • Kroon A.A.
        • de Leeuw P.W.
        • van Engelshoven J.M.
        Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis.
        Ann Intern Med. 2001; 135: 401-411
        • Orth D.N.
        Differential diagnosis of Cushing's syndrome.
        N Engl J Med. 1991; 325: 957-959
        • Jalal D.
        • Nolan C.
        • Schrier R.
        The kidney in hypertension.
        in: Schrier R. Renal and Electrolyte Disorders. 8th ed. Wolters Kluwer, Philadelphia, PA2016
        • Sacerdote A.
        • Weiss K.
        • Tran T.
        • Rokeya Noor B.
        • McFarlane S.I.
        Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management.
        Curr Hypertens Rep. 2005; 7: 212-218
        • Nieman L.K.
        • Biller B.M.
        • Findling J.W.
        • et al.
        The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
        J Clin Endocrinol Metab. 2008; 93: 1526-1540
        • Sontia B.
        • Mooney J.
        • Gaudet L.
        • Touyz R.M.
        Pseudohyperaldosteronism, liquorice, and hypertension.
        J Clin Hypertens. 2008; 10: 153-157
        • Sholter D.E.
        • Armstrong P.W.
        Adverse effects of corticosteroids on the cardiovascular system.
        Can J Cardiol. 2000; 16: 505-511
        • Warnock D.G.
        Liddle syndrome: genetics and mechanisms of Na+ channel defects.
        Am J Med Sci. 2001; 322: 302-307
        • Sahay M.
        • Sahay R.K.
        Low renin hypertension.
        Indian J Endocrinol Metab. 2012; 16: 728-739
        • Omura M.
        • Saito J.
        • Yamaguchi K.
        • Kakuta Y.
        • Nishikawa T.
        Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan.
        Hypertens Res. 2004; 27: 193-202
        • Sutton M.G.
        • Sheps S.G.
        • Lie J.T.
        Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series.
        Mayo Clin Proc. 1981; 56: 354-360
        • Chen G.
        • Wang J.
        • Weinberg L.
        • et al.
        Anaesthetic management of cardiac phaeochromocytoma: a case series.
        Int J Surg Case Rep. 2018; 51 ([published online August 19, 2018]): 134-138https://doi.org/10.1016/j.ijscr.2018.08.019
        • Lenders J.W.
        • Pacak K.
        • Walther M.M.
        • et al.
        Biochemical diagnosis of pheochromocytoma: which test is best?.
        JAMA. 2002; 287: 1427-1434
        • Appel L.J.
        • Moore T.J.
        • Obarzanek E.
        • et al.
        A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.
        N Engl J Med. 1997; 336: 1117-1124
        • Blumenthal J.A.
        • Babyak M.A.
        • Hinderliter A.
        • et al.
        Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study.
        Arch Intern Med. 2010; 170: 126-135
        • Blumenthal J.A.
        • Babyak M.A.
        • Sherwood A.
        • et al.
        Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids.
        Hypertension. 2010; 55: 1199-1205
        • Sacks F.M.
        • Svetkey L.P.
        • Vollmer W.M.
        • et al.
        Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.
        N Engl J Med. 2001; 344: 3-10
        • Ardery G.
        • Carter B.L.
        • Milchak J.L.
        • et al.
        Explicit and implicit evaluation of physician adherence to hypertension guidelines.
        J Clin Hypertens. 2007; 9: 113-119
        • Bell R.A.
        • Kravitz R.L.
        Physician counseling for hypertension: what do doctors really do?.
        Patient Educ Couns. 2008; 72: 115-121
        • Booth A.O.
        • Nowson C.A.
        Patient recall of receiving lifestyle advice for overweight and hypertension from their General Practitioner.
        BMC Fam Pract. 2010; 11: 8
        • Mellen P.B.
        • Palla S.L.
        • Goff Jr., D.C.
        • Bonds D.E.
        Prevalence of nutrition and exercise counseling for patients with hypertension. United States, 1999 to 2000.
        J Gen Intern Med. 2004; 19: 917-924
        • Johnson H.M.
        • Olson A.G.
        • LaMantia J.N.
        • et al.
        Documented lifestyle education among young adults with incident hypertension.
        J Gen Intern Med. 2015; 30: 556-564
        • Akoko B.M.
        • Fon P.N.
        • Ngu R.C.
        • Ngu K.B.
        Knowledge of hypertension and compliance with therapy among hypertensive patients in the Bamenda health district of Cameroon: a cross-sectional study.
        Cardiol Ther. 2017; 6: 53-67
        • Lozano L.
        • Tovar J.L.
        • Sampol G.
        • et al.
        Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial.
        J Hypertens. 2010; 28: 2161-2168
        • Liu L.
        • Cao Q.
        • Guo Z.
        • Dai Q.
        Continuous positive airway pressure in patients with obstructive sleep apnea and resistant hypertension: a meta-analysis of randomized controlled trials.
        J Clin Hypertens (Greenwich, Conn). 2016; 18: 153-158
        • Lloberes P.
        • Sampol G.
        • Espinel E.
        • et al.
        A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea.
        J Hypertens. 2014; 32 (discussion 1657): 1650-1657
        • Gaddam K.
        • Pimenta E.
        • Thomas S.J.
        • et al.
        Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
        J Hum Hypertens. 2010; 24: 532-537
        • McMahon E.J.
        • Bauer J.D.
        • Hawley C.M.
        • et al.
        A randomized trial of dietary sodium restriction in CKD.
        J Am Soc Nephrol. 2013; 24: 2096-2103
        • Shankar S.S.
        • Brater D.C.
        Loop diuretics: from the Na-K-2Cl transporter to clinical use.
        Am J Physiol Ren Physiol. 2003; 284: F11-F21
        • Cushman W.C.
        • Ford C.E.
        • Cutler J.A.
        • et al.
        Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
        J Clin Hypertens (Greenwich, Conn). 2002; 4: 393-404
        • Agodoa L.Y.
        • Appel L.
        • Bakris G.L.
        • et al.
        Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
        JAMA. 2001; 285: 2719-2728
        • Jafar T.H.
        • Stark P.C.
        • Schmid C.H.
        • et al.
        Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
        Ann Intern Med. 2003; 139: 244-252
        • Kidney Disease Outcomes Quality I
        K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
        Am J Kidney Dis. 2004; 43: S1-S290
      2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
        Lancet. 1997; 349: 1857-1863
        • Maschio G.
        • Alberti D.
        • Janin G.
        • et al.
        Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group.
        N Engl J Med. 1996; 334: 939-945
        • Kline G.A.
        • Pasieka J.L.
        • Harvey A.
        • So B.
        • Dias V.C.
        Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
        Ann Surg Oncol. 2013; 20: 2274-2278
        • Citton M.
        • Viel G.
        • Rossi G.P.
        • Mantero F.
        • Nitti D.
        • Iacobone M.
        Outcome of surgical treatment of primary aldosteronism.
        Langenbecks Arch Surg. 2015; 400: 325-331
        • Investigators A.
        • Wheatley K.
        • Ives N.
        • et al.
        Revascularization versus medical therapy for renal-artery stenosis.
        N Engl J Med. 2009; 361: 1953-1962
        • Bax L.
        • Woittiez A.J.
        • Kouwenberg H.J.
        • et al.
        Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
        Ann Intern Med. 2009; 150 (W150-841): 840-848
        • Cooper C.J.
        • Murphy T.P.
        • Cutlip D.E.
        • et al.
        Stenting and medical therapy for atherosclerotic renal-artery stenosis.
        N Engl J Med. 2014; 370: 13-22
        • Gafoor S.
        • Franke J.
        • Sievert H.
        The CORAL trial, round 2.
        J Am Coll Cardiol. 2015; 66: 2495-2497
        • Chabova V.
        • Schirger A.
        • Stanson A.W.
        • McKusick M.A.
        • Textor S.C.
        Outcomes of atherosclerotic renal artery stenosis managed without revascularization.
        Mayo Clin Proc. 2000; 75: 437-444
        • Orth D.N.
        Cushing's syndrome.
        N Engl J Med. 1995; 332: 791-803
        • Orth D.N.
        • Liddle G.W.
        Results of treatment in 108 patients with Cushing's syndrome.
        N Engl J Med. 1971; 285: 243-247
        • Pivonello R.
        • De Martino M.C.
        • Cappabianca P.
        • et al.
        The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
        J Clin Endocrinol Metab. 2009; 94: 223-230
        • Pivonello R.
        • Petersenn S.
        • Newell-Price J.
        • et al.
        Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
        Clin Endocrinol (Oxf). 2014; 81: 408-417
        • Estrada J.
        • Boronat M.
        • Mielgo M.
        • et al.
        The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.
        N Engl J Med. 1997; 336: 172-177
        • Razzaghy-Azar M.
        • Yau M.
        • Khattab A.
        • New M.I.
        Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
        J Steroid Biochem Mol Biol. 2017; 165: 145-150
        • Shen W.T.
        • Grogan R.
        • Vriens M.
        • Clark O.H.
        • Duh Q.Y.
        One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy.
        Arch Surg. 2010; 145: 893-897
        • Lenders J.W.
        • Duh Q.Y.
        • Eisenhofer G.
        • et al.
        Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2014; 99: 1915-1942
        • Egan B.M.
        • Zhao Y.
        • Li J.
        • et al.
        Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
        Hypertension. 2013; 62: 691-697
        • Daugherty S.L.
        • Powers J.D.
        • Magid D.J.
        • et al.
        The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension.
        Hypertension. 2012; 60: 303-309
        • Messerli F.H.
        Vasodilatory edema: a common side effect of antihypertensive therapy.
        Curr Cardiol Rep. 2002; 4: 479-482
        • Hanselin M.R.
        • Saseen J.J.
        • Allen R.R.
        • Marrs J.C.
        • Nair K.V.
        Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents.
        Hypertension. 2011; 58: 1008-1013
        • Ernst M.E.
        • Carter B.L.
        • Goerdt C.J.
        • et al.
        Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
        Hypertension. 2006; 47: 352-358
        • Barrios V.
        • Escobar C.
        Which thiazide to choose as add-on therapy for hypertension?.
        Integr Blood Press Control. 2014; 7: 35-47
        • Shah S.U.
        • Anjum S.
        • Littler W.A.
        Use of diuretics in cardiovascular disease: (2) hypertension.
        Postgrad Med J. 2004; 80: 271-276
        • Williams B.
        • MacDonald T.M.
        • Morant S.
        • et al.
        Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
        Lancet. 2015; 386: 2059-2068
        • Nishizaka M.K.
        • Zaman M.A.
        • Calhoun D.A.
        Efficacy of low-dose spironolactone in subjects with resistant hypertension.
        Am J Hypertens. 2003; 16: 925-930
        • Rossignol P.
        • Claggett B.L.
        • Liu J.
        • et al.
        Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.
        Am J Hypertens. 2018; 31: 407-414
        • Rosendorff C.
        • Lackland D.T.
        • Allison M.
        • et al.
        Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
        J Am Soc Hypertens. 2015; 9: 453-498
        • Cole R.T.
        • Kalogeropoulos A.P.
        • Georgiopoulou V.V.
        • et al.
        Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.
        Circulation. 2011; 123: 2414-2422
        • Badri T.
        • Kumar D.D.
        Minoxidil.
        StatPearls, Treasure Island, FL2018
        • Reichgott M.J.
        Minoxidil and pericardial effusion: an idiosyncratic reaction.
        Clin Pharmacol Ther. 1981; 30: 64-70
        • Bhatt D.L.
        • Kandzari D.E.
        • O'Neill W.W.
        • et al.
        A controlled trial of renal denervation for resistant hypertension.
        N Engl J Med. 2014; 370: 1393-1401
        • Azizi M.
        • Sapoval M.
        • Gosse P.
        • et al.
        Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.
        Lancet. 2015; 385: 1957-1965
        • Papademetriou V.
        • Tsioufis C.
        • Doumas M.
        Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom).
        Circ Res. 2014; 115: 211-214
        • Bisognano J.D.
        • Bakris G.
        • Nadim M.K.
        • et al.
        Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
        J Am Coll Cardiol. 2011; 58: 765-773